Regenerative cell therapy
When the cell is the product, the material is part of the product.
A small molecule arrives at its target unchanged. A cell has to survive manufacturing, survive delivery, and then survive the tissue it lands in. At every one of those steps it is sitting in a material, and that material is usually an afterthought.
The material acts at three points, not one.
Most attention goes to the cell itself: the source, the edit, the differentiation protocol. The material around it is chosen last and changed rarely, even though it is doing work at every stage.
Schematic of the cell therapy workflow and the role of the material at each stage.
Manufacturing
Expansion and differentiation happen on a surface. If that surface is animal derived and undefined, every batch carries a source of variation you cannot specify, and a component a regulator will ask about. A defined synthetic matrix removes both problems at once.
Delivery
Cells delivered as a free suspension disperse quickly and lose much of the dose before it can act. A designed carrier holds them where they were placed and shields them through injection.
Engraftment
Diseased tissue is inflamed, stiffened and short of the cues cells need. The material arriving with the cells is the only part of that environment anyone controls, and it can buy the time cells need to establish themselves.
Why this is a design problem, not a product problem
Each of those three jobs asks for something different from the material. Expansion wants a surface that keeps cells in the right state. Delivery wants something that flows through a needle and then holds. Engraftment wants something that degrades on the same schedule the tissue rebuilds.
No single catalogue formulation does all three, and the right combination changes with the cell type and the target tissue. That is exactly the search the platform performs.
The hardest case
In ALS, the cells arrive into tissue that is trying to kill them.
The aim is to replace motor neurons that have been lost. The tissue those cells are transplanted into is inflamed and hostile, and most do not survive long enough to connect. Everything the field has learned about cell survival converges on this one problem, which is why we chose it.
Regelife works on this with Professor Hideyuki Okano at Keio University, whose group pioneered iPSC derived neural transplantation. If matrix design holds here, it holds anywhere.
This work is at the research stage.
Schematic of attrition after cell transplantation. Illustrative only, not Regelife data.
In March 2026 Mark Ma presented this work at the Japan US ALS Forum in Tokyo, hosted by Tokyo Dome with Keio University's Regenerative Medicine Research Center and ALS Network, alongside Professor Okano and ALS Network CEO Sheri Strahl.
Read about the forum